成人起病癌症幸存者的内分泌健康
本文综述成人起病癌症长期幸存者(治愈或疾病长期控制且不太可能复发者)的内分泌并发症风险,包括下丘脑-垂体功能障碍、性腺功能减退、骨质疏松或代谢紊乱,尤其在强化肿瘤定向治疗时。症状从轻微亚临床到严重损害生活质量不等,许多内分泌病变长期未被诊断和治疗。文章强调提高认识、标准化筛查工具、易懂的治疗算法及内分泌科与肿瘤科紧密协作,并汇总现有实践指南、提出实用诊断方法。
要点
- 成人起病癌症长期幸存者内分泌并发症风险增加,强化肿瘤定向治疗时尤为明显。
- 常见内分泌病变包括下丘脑-垂体功能障碍、性腺功能减退、骨质疏松和代谢紊乱。
- 许多内分泌病变长期未被诊断和治疗,需提高认识、标准化筛查和内分泌-肿瘤科协作。
核心结论
- 成人起病癌症长期幸存者存在内分泌并发症风险,许多内分泌病变长期未被诊断和治疗,需提高认识、标准化筛查、易懂治疗算法及内分泌科与肿瘤科紧密协作以早期识别高危患者并实施适当治疗方案。
研究设计与样本
- 本文为综述,汇总成人起病癌症幸存者内分泌紊乱相关常见症状与疾病、现有实践指南,并提出实用诊断方法。
主要发现
- 长期幸存者(治愈或疾病长期控制且不太可能复发者)发生下丘脑-垂体功能障碍、性腺功能减退、骨质疏松或代谢紊乱等内分泌并发症的风险增加,尤其在应用强化肿瘤定向治疗时。
- 这些疾病的症状严重程度从轻微亚临床到高度有害不等,影响个体健康和生活质量。
- 许多内分泌病变通常可管理,但仍长期未被诊断和治疗。
临床怎么用
- 需要提高认识、标准化筛查工具、易懂的治疗算法以及内分泌科与肿瘤科紧密协作,以早期识别高危患者并实施适当治疗方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term survivors of cancer (ie, the patient who is considered cured or for whom the disease is under long-term control and unlikely to recur) are at an increased risk of developing endocrine complications such as hypothalamic-pituitary dysfunctions, hypogonadisms, osteoporosis, or metabolic disorders, particularly when intensive tumour-directed therapies are applied. Symptom severity associated with these conditions ranges from mild and subclinical to highly detrimental, affecting individual health and quality of life. Although they are usually manageable, many of these endocrine pathologies remain underdiagnosed and untreated for years. To address this challenge, a higher degree of awareness, standardised screening tools, comprehensible treatment algorithms, and a close collaborative effort between endocrinologists and oncologists are essential to early identify patients who are at risk, and to implement appropriate treatment protocols. This Review highlights common symptoms and conditions related to endocrine disorders among survivors of adult-onset cancer, provides a summary of the currently available practice guidelines, and proposes a practical approach to diagnose affected patients among this group.
引用
- Link-Rachner CS, Göbel A, Jaschke NP, et al. Endocrine health in survivors of adult-onset cancer. Lancet Diabetes Endocrinol. 2024. PMID: 38604215. doi:10.1016/S2213-8587(24)00088-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。